Novel antibody–drug conjugates for triple negative breast cancer-Reference-Cited by-同舟云学术

Novel antibody–drug conjugates for triple negative breast cancer

Published:2020-01 Issue: Volume:12 Page:175883592091598
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Nagayama Aiko¹,Vidula Neelima²,Ellisen Leif²,Bardia Aditya³^ORCID

Affiliation:

1. Department of Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan

2. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

3. Massachusetts General Hospital Cancer Center, Harvard Medical School, 10 North Grove Street, Boston, MA 02114-2621, USA

Abstract

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758835920915980

Reference53 articles.

1. Breast Cancer Treatment

2. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

3. Continuous cultures of fused cells secreting antibody of predefined specificity

4. Paul Ehrlich's Magic Bullets

5. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer drugs imperil Asian tree species;Science;2024-09-13

2. The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date);Discover Nano;2024-09-03

3. Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs;Advanced Science;2024-08-29

4. Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge;Diagnostics;2024-08-27

5. Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter;Cancer Chemotherapy and Pharmacology;2024-08-24